Peng Wei, Fan Hong, Wu Guoqiu, Wu Jianzhong, Feng Jifeng
Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing Medical University, No. 42 Baiziting Road, Nanjing, 210009, China.
Laboratory of Cancer Research, First People's Hospital of Yunnan, No. 175 Jinbi Road, Kunming, 650032, China.
Clin Exp Med. 2016 May;16(2):177-82. doi: 10.1007/s10238-015-0350-9. Epub 2015 Apr 12.
Diffuse large B cell lymphoma (DLBCL) is one of the most common malignancies worldwide. To date, there has been little progress in improving the overall survival of DLBCL patients. Emerging evidences have implicated that long noncoding RNAs (lncRNAs) have important regulatory roles in fundamental biological processes, and some of them are involved in cancer initiation, development and progression. This study was to investigate the expression of lncRNA PEG10 in a cohort of DLBCL patients to assess its clinical value and biological function in DLBCL. We first found that the expression of PEG10 was upregulated in DLBCL tumorous tissues and that cell lines compared with the normal. Moreover, we illustrated that PEG10 was significantly correlated with B symptoms, IPI score, CHOP-like treatment and rituximab. In addition, ROC(AUC) of PEG10 was up to 0.8228, implicating that PEG10 could be a diagnostic marker for distinguishing DLBCL from normal. Importantly, we verified that PEG10 was a key independent predictive factor for DLBCL prognosis from sizable samples through the longtime follow-ups. Furthermore, we revealed that knockdown of PEG10 expression by siRNA could lead to growth arrest and cell apoptosis in vitro. Our results suggested that PEG10 could represent a novel indicator of poor prognosis and might be served as a potential target for the diagnosis and gene therapy of DLBCL.
弥漫性大B细胞淋巴瘤（DLBCL）是全球最常见的恶性肿瘤之一。迄今为止，在提高DLBCL患者的总生存率方面进展甚微。新出现的证据表明，长链非编码RNA（lncRNAs）在基本生物学过程中具有重要的调节作用，其中一些参与癌症的发生、发展和进展。本研究旨在调查一组DLBCL患者中lncRNA PEG10的表达，以评估其在DLBCL中的临床价值和生物学功能。我们首先发现，与正常组织相比，PEG10在DLBCL肿瘤组织和细胞系中的表达上调。此外，我们还表明PEG10与B症状、国际预后指数（IPI）评分、CHOP样治疗和利妥昔单抗显著相关。此外，PEG10的受试者工作特征曲线下面积（ROC[AUC]）高达0.8228，这表明PEG10可能是区分DLBCL与正常组织的诊断标志物。重要的是，通过长期随访，我们从大量样本中验证了PEG10是DLBCL预后的关键独立预测因素。此外，我们发现通过小干扰RNA（siRNA）敲低PEG10表达可导致体外生长停滞和细胞凋亡。我们的结果表明，PEG10可能是预后不良的新指标，可能成为DLBCL诊断和基因治疗的潜在靶点。
